3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
9
Stomach Neoplasms
5
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Advanced Breast Cancer
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
15
Temozolomide
13
Specimen Handling
10
X-Rays
8
Biopsy
7
Nuclear Medicine Department, Hospital
6
Radiation
5
Phantoms, Imaging
5
erdafitinib
4
ulixertinib
3
trametinib
3
larotrectinib
3
dabrafenib
3
Radiotherapy
3
tipifarnib
2
selpercatinib
2
palbociclib
2
olaparib
2
ivosidenib
2
ensartinib
2
binimetinib
2
Surgical Procedures, Operative
2
Nivolumab
2
D2C7-(scdsFv)-PE38KDEL
2
vorasidenib
1
veliparib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
temsirolimus
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled